JPRN-UMIN000035853已完成未知
Retrospective study of alectinib on long-term prognosis in poor performance status patients with ALK positive, advanced/recurrent NSCLC - LOGIK1401-B
ung Oncology Group in Kyushu, Japan (LOGIK)0 个研究点目标入组 18 人开始时间: 2019年2月12日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 18
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Nothing particular
研究者
相似试验
已完成
2 期
A-LiquidJPRN-jRCT2080225060Department of Thoracic Oncology, National Cancer Center Hospital East25
已完成
不适用
PhaseII safety and efficacy study of alectinib in poor performance status patients with ALK positive, advanced NSCLCon-Small Cell Lung CancerJPRN-UMIN000015094ung Oncology Group in Kyushu, Japan (LOGIK)17
已完成
4 期
Prospective study on effects of abrocitinib treatment of moderate to severe atopic dermatitis on skin barrier functioL20.9Atopic dermatitis, unspecifiedDRKS00028981niversitätsklinikum Schleswig-Holstein, Campus Kiel, Abteilung für Dermatologie, Allergologie und Venerologie20
招募中
不适用
Retrospective study for Lenvatinib for unresectable thyroid cancersnresectable thyroid cacersJPRN-UMIN000030969Kyoto Prefectural University of Medicine50
已完成
不适用
The Efficacy and Safety of Alectinib in Clinical Practice ; Comparision to Crizotinib, in A Multicenter Retrospective Study.ALK rearranged non-small-cell lung cancerJPRN-UMIN000036255Respiratory Centor, Matsusaka Municipal Hospital61